Biotech company Biogen (NASDAQ:BIIB) will be announcing earnings results tomorrow morning. Here’s what to look for.

Monoclonal antibodies have emerged as a promising approach in the fight against Alzheimer's disease, offering hope for ...

Bernstein initiated coverage of Biogen (BIIB) with a Market Perform rating and $160 price target For the past five years, Biogen “has lived ...

Bio-Thera Solutions has signed an exclusive licence and commercialisation agreement with Intas Pharmaceuticals for BAT2506 in ...

The fourth-quarter earnings season for the biotech sector is in full swing this week. A few bigwigs have already reported results. Among these, Bristol Myers reported better-than-expected ...

That’s the conclusion of hiring managers at four of the state’s leading life sciences companies who spoke at a recent career ...

Explore the potential of monoclonal antibodies in Alzheimer’s treatment, including breakthroughs and challenges in this ...

In a report released on February 7, Umer Raffat from Evercore ISI maintained a Buy rating on Biogen (BIIB – Research Report). The company’s ...

We recently compiled a list of the 12 Best Healthcare Stocks to Buy According to Analysts. In this article, we are going to ...

The stock's fall snapped a two-day winning streak.